2seventy Bio, INC 10-K annual reports
Annual reports — audited financials, the full risk-factor list, and management’s account of the year.
2seventy bio files an amendment to its 2024 Annual Report on Form 10-K to include previously omitted information regarding directors, executive officers, and corporate governance.
2seventy bio, Inc. reports its 2024 financial results, highlighting Abecma's commercial performance and strategic realignment, while awaiting a proposed acquisition by Bristol-Myers Squibb (BMS).
2seventy bio modifies its royalty payment terms with the National Institutes of Health and strategically realigns to concentrate on the commercialization of Abecma.